G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.
G for georgiamune.

Company news

Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407

Press Release

GAITHERSBURG, MD, September 24, 2024 – Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first participant has been dosed with GIM-407 in a first-in-human, phase 1 clinical trial in healthy volunteers, which is the stepping stone of the clinical development plans to develop it for patients with autoimmune diseases.

Sep 24, 2024
READ MORE

Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531

Press Release

Gaithersburg, MD, July 30, 2024 – Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first patient has been dosed with GIM-531 in a first-in-human, phase 1 clinical trial for the treatment of advanced cancer patients.

July 30, 2024
READ MORE

Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch

Press Release

Gaithersburg, MD, May 29, 2024 – Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-531, a first-in-class oral treatment that selectively targets T-regulatory cells and spares other immune cells such as CD4 and CD8.

May 29, 2024
READ MORE

Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing

Press Release

Gaithersburg, MD, August 09, 2023 - Today, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases.

August 9, 2023
READ MORE
Georgiamune Inc.
942 Clopper Rd
Gaithersburg, MD 20878
United States
[email protected]Contact
© Georgiamune Inc 2023